Core Laboratories NV Stock News

Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?

Natixis Advisors L.P. decreased its position in Core Laboratories Inc. (NYSE:CLB – Free Report) by 32.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The ins

Core Laboratories Inc. (CLB) Q1 2024 Earnings Call Transcript

Core Laboratories' (CLB) second-quarter 2024 revenues are anticipated to be in the $130-$136 million range, while the operating income is estimated to be in the band of $14.5-$17.3 million.

FIRST QUARTER REVENUE OF $129.6 MILLION, UP MODESTLY SEQUENTIALLY AND YEAR-OVER-YEAR FIRST QUARTER OPERATING INCOME OF $8.6 MILLION; EX-ITEMS, $14.9 MILLION, FLAT SEQUENTIALLY, UP 3% YEAR-OVER-YEAR FI

Core Laboratories (CLB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Core Laboratories Inc. (CLB) Q4 2023 Earnings Call Transcript

Core Laboratories' (CLB) first-quarter 2024 revenues are anticipated in the $122-$128 million range, while the operating income is estimated in the band of $11.8-$14.3 million.

While the top- and bottom-line numbers for Core Laboratories (CLB) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metri

Core Laboratories (CLB) came out with quarterly earnings of $0.19 per share, missing the Zacks Consensus Estimate of $0.20 per share. This compares to earnings of $0.20 per share a year ago.

FOURTH QUARTER REVENUE OF $128.2 MILLION, UP 2% SEQUENTIALLY FOURTH QUARTER OPERATING INCOME OF $14.6 MILLION; EX-ITEMS, $15.0 MILLION, DOWN 6% SEQUENTIALLY FOURTH QUARTER OPERATING MARGINS, EX-ITEMS,

Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).